Read on Twitter
$LOAC Thread: My new swing that I will be holding through January. This is my favorite non EV SPAC for many reasons
A little background: $LOAC is merging with @4dpharmaplc in mid January 2021. 4dpharma is currently trading on the LSE under #DDDD. They are a world leader in the development of Live Biotherapeutics.
4Dpharmas Live Biotherapeutic products (LBPs)are orally delivered single strains of bacteria that are naturally found in a healthy human gut.4D developed MicroRx, which is a proprietary platform that rationaly identifies LB based on a deep understanding of function and mechanism.
In 2017 Neil Woodford- a UK fund manager, who held a big position in 4dpharma sold all his holdings to Acacia Research, which then were liquidated
at a rapid pace causing the share price to take a huge hit. Headlined as âOne of Europes Biggest Investment Scandalsâ for a decade.
With that being said, #DDDD has been trading at a fraction of its highs in SP since then. Currently, itâs a little bit higher than it was when Neil Woodford first invested in 4D and said that @4dpharmaplc is âextremely undervaluedâ But recently, it started forming an uptrend.
Now lets get into a little bit of the catalysts for @4dpharmaplc because there a shit ton of them.
@4dpharmaplc has six clinical programmes. 1. Phase I/II study of MRx0518 in combination with KEYTRUDA (pembrolizumab) in solid tumours. 2. a Phase I study of MRx0518 in a neoadjuvant setting for patients with solid tumours.
3. a Phase I study of MRx0518 in patients with pancreatic cancer. 4. a Phase I/II study of MRx-4DP0004 in asthma. 5. a Phase II study of MRx-4DP0004 in patients hospitalised with COVID-19 (Cough Cough Covid Play) 6. BlautixÂź in Irritable Bowel Syndrome (IBS) which has completed a
successful Phase II trial. The timeline for these catalysts are below. All of them are in the near term.
They are working on a number of Preclinical-stage programmes, which include candidates for CNS disease such as Parkinson's disease and other neurodegenerative conditions. â4D continues to make progress of the FIRST -in-human clinical trial in Parkinsonâs disease patients.â
Another important piece of information is that 4D has a research collaboration with MSD, a tradename of Merck & Co., Inc., Kenilworth, NJ, USA, to discover and develop Live Biotherapeutics for vaccines. Also $mrk has a 6% stake in @4dpharmaplc
This is mainly bc 4Ds MRx0518 enhances the effectiveness of their multibillion dollar drug, Keytruda. This will play a huge role in the future for a possible $mrk buy out like they just did with VelosBio for $2.7b. 4D is very undervalued compared to their peers in the same space.
Here are two videos and an article that I definitely suggest watching/reading. It will give you a good insight on what @4dpharmaplc has been up to. and and https://www.proactiveinvestors.co.uk/companies/amp/news/936945?__twitter_impression=true
And on top of all of this, they have 1000+ patents- the most in the microbiome sector 
The last thing I will leave you with is this. This alone will make the SP of $LOAC skyrocket 30m market cap, 500k float, 2.6 shares outstanding
We saw what happened with $BRPA recently when the volume poured in. Well weâre next 
We saw what happened with $BRPA recently when the volume poured in. Well weâre next
Mathew Chen-CEO of $loac has a reputable background as well. Definitely will be a tremendous help for #DDDD with their networking once listed on Nasdaq
Good clip of Duncan talking about how they are opening the door for more and more partnerships in the future $loac #DDDD
In response to being frustrated with the share price of @4dpharmaplc: âWe are doing all the right things. Weâve got a lot of trials ongoing. Weâve got a really fantastic board and massive support. Weâve got a great partner in $mrk and we WILL bring in more partners
$loac #DDDD
$loac #DDDD
$loac #dddd Duncan will drop some positive news along with the Nasdaq listing and you canât@change my mind! Theyâve been preparing for this because they know some US institutions were iffy about going in on an Aim stock
